Solubility Enhancement of Brexpiprazole for Schizophrenia using HPβ Cyclodextrin Ternary Complexation
DOI:
https://doi.org/10.30827/ars.v66i2.32043Keywords:
Schizophrenia, Brexpiprazole, Ternary complex, Phase solubility, Dissolution rateAbstract
Introduction: The present study focuses on the solubility and dissolution rate enhancement of Brexpiprazole with Hydroxy Propyl β-cyclodextrin and succinic acid as a solubiliser for schizophrenia.
Materials & Method: Brexpiprazole was obtained as a gift sample from CTX Life sciences, Sachin, Surat. Hydroxypropyl beta cyclodextrin was gifted by Good Health Pvt. Ltd Sachin, Surat. Binary and ternary complexes were prepared using three different methods and characterized using the fourier transform infrared spectroscopy, differential scanning calorimetry, X-ray diffraction and invitro dissolution studies.
Results: It was observed that among different ratios of drug and polymer used, 1:5 ratio of drug and polymer for binary complex was found to be the optimized and solvent evaporation method gave the best results. The ternary complex was then prepared using this ratio in different concentration of succinic acid (0.25, 0.5 and 1 % w/w) and optimum concentration of succinic acid as a solubiliser was of 1 %. The drug release was found to be maximum 92 % as compared to binary complex. The fourier transform infrared spectroscopy, differential scanning calorimetry and X-ray diffraction results confirmed the formation of stable complex.
Conclusions: It was concluded that ternary complex had maximum drug release of 92% at the end of 60 minutes resulting in solubility and dissolution rate enhancement.
Downloads
References
Read J, van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia. A literature review with theoretical and clinical implications. Acta Psychiatr Scand. 2005;112(5):330–50. doi: 10.1111/j.1600-0447.2005.00634.x. DOI: https://doi.org/10.1111/j.1600-0447.2005.00634.x
Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014; 2014:869269. doi: 10.1155/2014/869269. DOI: https://doi.org/10.1155/2014/869269
Deshmukh AS, Tiwari KJ, Mahajan VR. Solubility Enhancement Techniques for Poorly Water-Soluble Drugs. Int J Pharm Sci Nanotechnol. 2017;10(3):3701–8. Doi:10.37285/ijpsn.2017.10.3.1 DOI: https://doi.org/10.37285/ijpsn.2017.10.3.1
Turunen E. Cyclodextrins in Fast- Dissolving Drug Formulations for Intraoral Administration. Publications of the University of Eastern Finland. Dissertations in Health Sciences 229; 2014.
Manne ASN, Hegde AR, Raut SY, Rao RR, Kulkarni VI, Mutalik S. Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs. Drug Deliv Transl Res. 2021;11(3):1273-1287. doi: 10.1007/s13346-020-00854-w. DOI: https://doi.org/10.1007/s13346-020-00854-w
Chaudhary A, Nagaich U, Gulati N, Sharma VK, Khosa RL. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review. J Adv Pharm Educ Res. 2012;2(1):32–67.
Chaudhary VB, Patel J.K. Cyclodextrin inclusion complex to enhance solubility of poorly water soluble drugs. A Review. Int J Pharm Sci Res. 2013;4(1): 68-76. Doi: 10.13040/IJPSR.0975-8232 DOI: https://doi.org/10.13040/IJPSR.0975-8232
Kumar SK, Raju PY, M Sushma. Dissolution Enhancement of Poorly Soluble Drugs by Using Complexation Technique-A Review. J. Pharm. Sci. & Res. 2013; 5(5): 120 – 124.
Sharma GS, Srikanth MV, Sunil SA, Rao NS, Murthy KR. Dissolution rate enhancement of poorly soluble gliclazide by complexation with hydroxy propyl β cyclodextrin. Res J Pharm Biol Chem Sci. 2011;2(3):814-23.
Basavaraj S, Sihorkar V, Shantha Kumar TR, Sundaramurthi P, Srinivas NR, Venkatesh P, et al. Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxy propyl-β-cyclodextrin: Selection of meglumine, a polyhydroxy base, as a novel ternary component. Pharm Dev Technol. 2006;11(4):443–51. doi:10.1080/10837450600770577. DOI: https://doi.org/10.1080/10837450600770577
Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1–2):1–11. doi: 10.1016/j.ijpharm.2006.10.044. DOI: https://doi.org/10.1016/j.ijpharm.2006.10.044
Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry. 2018;26(1):92-94. doi: 10.1177/1039856217732473. DOI: https://doi.org/10.1177/1039856217732473
Eaves S, Rey JA. Brexpiprazole (Rexulti): A new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder. P T. 2016;41(7):418-422.
Loh Gok, Tan YTF, Peh KK. Enhancement of norfloxacin solubility via inclusion complexation with β-cyclodextrin and its derivative hydroxypropyl-β-cyclodextrin. Asian J Pharm Sci. 2016 Aug 1;11(4):536–46. Doi: 10.1016/j.ajps.2016.02.009 DOI: https://doi.org/10.1016/j.ajps.2016.02.009
Jagdale SK, Dehghan MH, Paul NS. Enhancement of dissolution of fenofibrate using complexation with hydroxy propyl β-cyclodextrin. Turk J Pharm Sci. 2019 Mar 1;16(1):48–53. doi: 10.4274/tjps.60490. DOI: https://doi.org/10.4274/tjps.60490
Pathak SM, Musmade P, Dengle S, Karthik A, Bhat K, Udupa N. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation. Eur J Pharm Sci. 2010;41(3-4):440-451. doi: 10.1016/j.ejps.2010.07.013. DOI: https://doi.org/10.1016/j.ejps.2010.07.013
Kaushik, S., Verma, R., Purohit, D. et al. (2020). Development of binary and ternary complex of cefuroxime axetil with cyclodextrin for improving pharmaceutical characteristics. International Journal of Applied Pharmaceutics, 12(6),107–117. Doi: 10.22159/ijap.2020v12i6.38927 DOI: https://doi.org/10.22159/ijap.2020v12i6.38927
Patel SG, Rajput SJ. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS PharmSci Tech. 2009;10(2):660–9. Doi: 10.1208/s12249-009-9249-7 DOI: https://doi.org/10.1208/s12249-009-9249-7
Jafar, Mohammed & Salahuddin, Mohammed & Kayed, M.T. & Ahmed, N. & Al-Eid, H.A. & Al-Qarross, A.H. Solid State Analysis and In-Vitro Dissolution Behavior of MeloxicamHydroxy Propyl Beta Cyclodextrin-Ethanolamines Ternary Complexes. International Journal of Pharmaceutical Quality Assurance. 2018 Mar 30;9(01). Doi: 10.25258/ijpqa.v9i01.11919 DOI: https://doi.org/10.25258/ijpqa.v9i01.11919
Patel HM, Suhagia BN, Shah SA, Rathod IS, Parmar VK. Preparation and characterization of etoricoxib-β-cyclodextrin complexes prepared by the kneading method. Acta Pharmaceutica. 2007;57(3):351–9. doi: 10.2478/v10007-007-0028-2. DOI: https://doi.org/10.2478/v10007-007-0028-2
Chowdary, K & Naresh, A. A Factorial study on the effects of β Cyclodextrin, PVP K30 and SLS on the solubility and dissolution rate of efavirenz. Int J App Bio Pharm Technol. 2010;2: 228-34.
Crestani De Miranda J, Elyan T, Martins A, Veiga F, Gomes Ferraz H. Cyclodextrins and ternary complexes: technology to improve solubility of poorly soluble drugs. Braz. J. Pharm. Sci.2011; 47 (4). Doi:10.1590/S1984-82502011000400003 DOI: https://doi.org/10.1590/S1984-82502011000400003
Avdeef A. Absorption and Drug Development: Solubility, Permeability, and Charge State. Hoboken, NJ: John Wiley & Sons; 2003. DOI: https://doi.org/10.1002/047145026X
He R, Craig DQ. An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry. J Pharm Pharmacol. 2001;53(1):41-48. doi:10.1211/0022357011775172. DOI: https://doi.org/10.1211/0022357011775172
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 amit patel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
